Antiviral therapeutic drug combinations
AssigneesThe University of Tulsa, Biocharged Ventures, LLC
InventorsRobert J. SHEAFF, Ian MITCHELL
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for the treatment or prevention of viral infections via the use of chemical substances administered in a combinatory fashion for the suppression, inhibition, and elimination of viral loads. These compositions and methods use a glycolysis inhibitor (e.g., 2-deoxy-D-glucose (2-DG)) in combination with one or more compounds comprising one or more aromatic rings and at least one alkylamino(C≤12) group or substituted alkylamino(C≤12) group.
Claims30
A method of treating a patient having a coronavirus infection or preventing a coronavirus infection in a patient, the method comprising administering to the patient an effective amount of a first pharmaceutical therapy comprising a glycolysis inhibitor and a second pharmaceutical therapy comprising a compound having one or more aromatic rings and at least one alkylamino(C≤12) group or substituted alkylamino(C≤12) group.
A pharmaceutical composition comprising:
- (a) a glycolysis inhibitor;
- (b) a compound having one or more aromatic rings and at least one alkylamino(C≤12) group or substituted alkylamino(C≤12) group;
- and
- (c) a pharmaceutically acceptable carrier.
A kit of part, the kit comprising:
- (a) a first pharmaceutical composition comprising a glycolysis inhibitor;
- (b) a second pharmaceutical composition comprising a compound having one or more aromatic rings and at least one alkylamino(C≤12) group or substituted alkylamino(C≤12) group,
- wherein the first pharmaceutical composition and the second pharmaceutical composition are provided as separate components of the kit.
Dependencies are inferred from the claim text.